Psoriatic Arthritis
Largest, most representative PsA data registry available for licensing, analytics, and collaboration
Research-Grade RWD in PsA
Disease with no cure
With no cure for PsA, early diagnosis and effective treatment are the best ways to help reduce damaging effects and improve patients’ quality of life.
71,000+
PsA patients followed prospectively with deep clinical, lab, and other linked data with a mean follow-up of 9 years.
481,000+
PsA patients in the OM1 Real-World Data Cloud that can be used for modeling, analysis, and other research purposes
*Counts are subject to change
Specialized Data
Why OM1 PsA?
Sample Use Cases
» Feasibility |
» Comparative Effectiveness |
» Passive Safety |
» Natural History |
Interested in exploring Psoriasis patients too?
Check out our Dermatology network
Webinar: Real-World Data for R&D for Autoimmune & Chronic Diseases
Posters
- Poster (Collaboration with Amgen): Cavanaugh C, Orroth K, Kumparatana P, Klyachkin Y, Colgan S, Deignan C, Cordey M, Mehta N; A Real World Analysis of Apremilast and Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis, Including Impact on Weight Loss by Diabetic Status. Presented at European Academy of Dermatology and Venereology, Berlin, Germany; October 11-14, 2023.
- AAD 2023: Patient-Reported Outcomes and Changes in DMARD Therapy Among Psoriatic Arthritis Patients Treated in Routine Clinical Practice
Award-Winning Research Team
Our team of award-winning researchers has authored hundreds of publications, including scientific posters, articles in peer-reviewed journals, white papers, and books.